Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Nikkei rises to more than 1-month high; automakers, tech shares gain

2018-07-18 reuters
TOKYO, July 18 (Reuters) - Japan’s Nikkei share average advanced to a more than one-month high on Wednesday as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the yen.
7261 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY

0
Nikkei jumps to over 1-month high

2018-07-18 thehindubusinessline
Japan's Nikkei share average soared to a more than one-month high on Wednesday morning as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the yen.
7261 PCRFY 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY

0
Nikkei rises to more than 1-month high as exporters get boost from weak yen

2018-07-18 reuters
* Takara, Tokyo Dome fall after brokerage takes guess to be excluded from Nikkei index in Oct
7261 PCRFY 9681 ADTTF MZDAY TM TYT TOYOF 2531 TTDKF TKHIY MZDAF 7203 ATEYY

14
Ford to Pay $299.1 Million to Settle Takata Consumer Lawsuit - Bloomberg

2018-07-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7261 MZDAY TM TYT TOYOF DDAIF VLKAF GM.WS.A GM.WS.B MZDAF GM.WS.C 7203 GM GM.WSB

0
Ford agrees to US$299.1 million US Takata air bag settlement

2018-07-16 channelnewsasia
WASHINGTON: Ford Motor Co agreed to a so-called economic loss settlement of US$299.1 million covering at least 6 million U.S. vehicles with potentially faulty Takata air bag inflators, court documents filed in a federal court in Miami on Monday show.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

0
Ford agrees to $299.1 million U.S. Takata 'economic loss' settlement

2018-07-16 reuters
WASHINGTON (Reuters) - Ford Motor Co (F.N) agreed to a $299.1 million so-called economic loss settlement covering at least 6 million U.S. vehicles with potentially faulty Takata air bag inflators, court documents filed in a federal court in Miami on Monday show.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

0
Mazda restarts auto plants in flood-hit parts of western Japan

2018-07-12 japantimes.co.jp
OSAKA – Mazda Motor Corp. resumed operations at its plants in western Japan on Thursday in the wake of devastating flooding and landslides.
7261 MZDAY MZDAF

2
Nikkei rises to 1-1/2-week high on Wall Street rally

2018-07-10 thehindubusinessline
Yahoo Japan Corp was up 10 per cent after rising as much as 11.66 per cent.
7261 MZHOF SMFG HCTHY ICLQY SFTBF SMFNF TOELY 8306 4689 532281 YAHOY TOELF MBFJF SFTBY ADTTF MZDAY 532822 YAHOF 8316 MZDAF HCLTECH IDEA MUFG 8411 9984 8035 ATEYY MTU MFG

0
Rescuers race to find survivors after Japan floods kill at least 114

2018-07-09 theedgemarkets
KURASHIKI, Japan (July 9): Rescuers in Japan dug through mud and rubble on Monday, racing to find survivors after torrential rain unleashed floods and landslides that killed at least 114 people, with dozens missing.
7261 MZDAY MZDAF

4
Nikkei rebounds to 1-week high after U.S. jobs data; Nissan tumbles

2018-07-09 reuters
TOKYO, July 9 (Reuters) - Japan’s Nikkei share average rebounded to one-week highs on Monday as investors took heart from U.S. jobs growth, while Eisai extended its gains to its daily-limit high on optimism for its Alzheimer’s drug.
7261 PCRFY MZDAY TTDKF BIIB 8306 MZDAF MUFG MBFJF MTU

4
Nikkei rebounds to 1-week high on US jobs data

2018-07-09 thehindubusinessline
Japan's Nikkei share average rebounded to a one-week high on Monday morning as investors took heart from US jobs growth, while Eisai extended its gains to its daily-limit high on optimism for its Alzheimer's drug.
7261 MZHOF PCRFY MZDAY TTDKF BIIB 8306 MZDAF MUFG 8411 MBFJF MTU MFG

4
Nikkei rebounds to 1-week high after U.S. jobs data; Eisai jumps

2018-07-09 reuters
TOKYO, July 9 (Reuters) - Japan’s Nikkei share average rebounded to one-week highs on Monday morning as investors took heart from U.S. jobs growth, while Eisai extended its gains to its daily-limit high on optimism for its Alzheimer’s drug.
7261 MZHOF PCRFY MZDAY TTDKF BIIB 8306 MZDAF MUFG 8411 MBFJF MTU MFG

0
At least 64 killed in Japan after 'unprecedented' rain, dozens missing - Channel NewsAsia

2018-07-08 channelnewsasia
TOKYO: The death toll from unprecedented rains in Japan rose to at least 64 on Sunday after rivers burst their banks and forced several million people from their homes, media reports said, with more rain set to hit some areas for at least another day.
7261 PCRFY MZDAY MZDAF

0
Death Toll Rises to 54 as `Historic' Floods Continue in Japan - Bloomberg

2018-07-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7261 PCRFY MZDAY TM TYT TOYOF MMTOY MZDAF 9437 7203 NTDMF 7211 MMTOF DCM

0
Mazda halts production at Hiroshima plant as floods hit west Japan, 11 dead

2018-07-07 livemint
Tokyo: At least 11 people have died and thousands have fled their homes because of flooding in western Japan, with Mazda Motor Corp. in Hiroshima halting production at the weekend.
7261 MZDAY TM MZDAF 7203 TYT TOYOF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 578787103